Neuroinfectious Disease
5 cases on empiric treatment decisions made before a confirming test returns — HSV encephalitis, bacterial meningitis, botulism, suspected PML in a natalizumab patient, and toxoplasmosis versus lymphoma in advanced HIV — choose a case below to open its full multi-voice debate.
A clinical picture concerning for herpes encephalitis, an HSV PCR still a day away, and a mild volume-depletion complication that turns urgent treatment into a question of how to start it, not whether.
A new seizure makes a head CT appropriate before the lumbar puncture — the team has to decide, in real time, whether that scan is allowed to become the reason antibiotics and dexamethasone wait.
A shared-meal cluster and a rapidly progressing descending paralysis make botulism the leading diagnosis long before any laboratory test can confirm it — and the antitoxin that treats it only works on toxin that hasn’t bound yet.
A natalizumab-treated MS patient’s new, subacute neurologic decline looks more like PML than a relapse — and plasma exchange clears the drug faster, but nobody is certain that doing so actually helps rather than just moving the danger earlier.
A solitary ring-enhancing brain lesion in a man with untreated, far-advanced HIV sits right where the usual empiric-toxoplasmosis playbook stops being an easy call — a solitary lesion is exactly the finding the literature flags as tilting the odds toward the diagnosis empiric treatment could miss.